Among patients with COPD and type 2 inflammation, investigator-reported emphysema did not change benefits seen with dupilumab ...

The biotech industry faces a mix of longstanding and novel political challenges amid President Donald Trump’s second term.

California says the sale of 23andMe to a nonprofit formed by the company's former CEO would skirt a state law specifically ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)--Jun 16, 2025-- ...

Roche/Genentech entered into a Licensing, Development, and Commercialization agreement with Prothena in December 2013 to develop and commercialize monoclonal antibodies targeting aggregated ...

The initial report of monotherapy with the BCL-2 inhibitor venetoclax showed it had durable clinical activity and favorable ...

Multiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory ...

Genentech announced a third round of layoffs, affecting 143 jobs, as part of its strategic workforce adjustments, amid broader job cuts across various sectors in Northern California.

Those adjustments just keep coming. As SFGATE reported, Genentech announced 436 layoffs in April 2024, and 93 more layoffs ...

Reduced doses in antifibrotic therapy for patients with idiopathic pulmonary fibrosis did not significantly impact outcomes, ...